The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL.

Blood
Carsten MüllerMarcel Reiser

Abstract

Pharmacokinetics of 8 doses of rituximab (375 mg/m(2)) given in combination with 2-week cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone/prednisolone (CHOP-14) was determined by ELISA in 20 elderly patients with diffuse large B-cell lymphoma (DLBCL) 10 minutes before and after each infusion and 1 week and 1, 2, 3, 6, and 9 months after the last infusion. Population pharmacokinetic modeling was performed with nonlinear mixed-effect modeling software (NONMEM VI). Concentration-time data were fitted into an open 2-compartment model and total clearance, central compartment volume, intercompartment clearance, and volume of distribution at steady-state (Vd(ss)) were investigated. Total clearance was 9.43 mL/h and Vd(ss) was 9.61 l. Rituximab clearance was reduced (8.21 mL/h vs 12.68 mL/h; P = .003) and elimination half-life was prolonged in women compared with men (t(1/2β) = 30.7 vs 24.7 days; P = .003). Body weight also affected Vd(ss) (0.1 l increase of Vd(ss) per kilogram above median of 75 kg). A sex-dependent effect and the higher weight of males contribute to their faster rituximab clearance, which might explain why elderly males benefit less from the addition of rituximab to CHOP than females. This trial was ...Continue Reading

References

Jul 8, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K TobinaiT Murate
Nov 18, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N L BerinsteinD Shen
Aug 12, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L D PiroV Jain
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Jan 28, 2004·Annual Review of Pharmacology and Toxicology·Monica GandhiTerrence F Blaschke
Apr 28, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K TobinaiUNKNOWN IDEC-C2B8 Japan Study Group
Aug 23, 2005·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Petra Jilma-StohlawetzBernd Jilma
Jun 7, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas M HabermannSandra J Horning
Feb 9, 2007·Critical Reviews in Oncology/hematology·Guillaume CartronChantal Le Guellec
Jan 30, 2008·The Lancet Oncology·Michael PfreundschuhUNKNOWN German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
Aug 8, 2009·Fundamental & Clinical Pharmacology·Hélène BlascoChantal Le Guellec
Jul 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtNorbert Schmitz
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rafael BejarBenjamin L Ebert
Feb 5, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C ZwickUNKNOWN German High-Grade Non-Hodgkin Lymphoma Study Group

❮ Previous
Next ❯

Citations

Feb 14, 2014·The Lancet Oncology·Kensei Tobinai
Oct 24, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtBertram Glass
Apr 19, 2012·Haematologica·Ulrich JägerUNKNOWN Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) Investigators
Mar 25, 2014·Haematologica·Daniel CatovskyMonica Else
Aug 29, 2013·Future Oncology·Chan Y CheahJohn F Seymour
Feb 26, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F HongB S Kahl
Dec 5, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L WeissA Egle
Jun 15, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N MurawskiC Zwick
Sep 13, 2012·Leukemia & Lymphoma·Constantine S Tam, Michael J Keating
Oct 16, 2014·Leukemia & Lymphoma·Umar Farooq, Ginna G Laport
Dec 17, 2015·Leukemia & Lymphoma·Katja RöschDirk Hasenclever
Sep 6, 2014·Expert Opinion on Biological Therapy·Tim IllidgeJamie Honeychurch
Dec 19, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·I FleuryC Thieblemont
Jul 21, 2015·Cancer Treatment Reviews·Tim IllidgeGuillaume Cartron
Sep 17, 2013·British Journal of Haematology·Bertrand CoiffierUNKNOWN 415 study investigators
Feb 26, 2013·British Journal of Clinical Pharmacology·Florent PuissetJacques Pourrat
May 13, 2014·Clinical and Translational Science·Milena KrajnovićKoviljka Krtolica
Sep 20, 2015·Annals of Hematology·Nobuhiko NakamuraHisashi Tsurumi
Aug 13, 2015·Cancer Metastasis Reviews·Fernando MendesManuel Santos Rosa
Jan 1, 2012·Scientifica·Christiane S Hampe
Jun 10, 2015·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Marshall BehrensVeena Taneja
Dec 30, 2015·British Journal of Clinical Pharmacology·Guillemette BernadouDavid Ternant
May 15, 2015·Science Translational Medicine·Liping L SunAllen J Ebens

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.